MedTrace Logo

Automated Quantification of Coronary Artery Calcifications on Radiotherapy Planning CTs for Cardiovascular Risk Prediction in Breast Cancer Patients: the BRAGATSTON Study

NCT03206333 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 16000

Last updated 2024-02-06

No results posted yet for this study

Summary

The aim of the BRAGATSTON study is to provide a low cost tool for measuring CAC in breast cancer patients, thereby identifying patients at increased risk of CVD. Breast cancer patients and doctors can act upon this, by adapting the treatment and/or by adopting cardioprotective interventions. Hereby, the burden of CVD in breast cancer survivors can be reduced and better overall survival rates can be achieved.

Conditions

Sponsors & Collaborators

  • Erasmus Medical Center

    collaborator OTHER

  • Radboud University Medical Center

    collaborator OTHER

  • UMC Utrecht

    lead OTHER

Principal Investigators

  • Helena M. Verkooijen, MD, PhD · Imaging Division, University Medical Center Utrecht, Utrecht

  • Ivana Išgum, PhD · Image Sciences Institute, University Medical Center Utrecht, Utrecht

  • Luca Incrocci, MD, PhD · Department of Radiation Oncology, Erasmus Medical Center, Rotterdam

  • Hanneke Meijer, MD, PhD · Department of Radiation Oncology, Radboudumc, Nijmegen

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-01
Primary Completion
2020-03-01
Completion
2020-03-01

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03206333 on ClinicalTrials.gov